| Raising high-density lipoprotein cholesterol with inhibitors of cholesteryl ester transfer protein - a new approach to coronary artery disease. | |
| | |
MedLine Citation:
|
PMID: 15461565 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Although the low-density lipoprotein (LDL) cholesterol-lowering statins reduce the mortality and morbidity associated with coronary artery disease, considerable mortality and morbidity remains. Increasing high-density lipoprotein (HDL) cholesterol reduces coronary artery disease mortality and morbidity. In healthy subjects with mild dyslipidaemia, treatment with JTT-705 decreased cholesteryl ester transfer protein (CETP) activity, increased HDL-cholesterol and decreased LDL-cholesterol. Similarly, another CETP inhibitor, torcetrapib 120 mg/day has recently been shown to increase HDL-cholesterol by 46%, decrease LDL-cholesterol by 8% and have no effect on triglycerides in subjects with HDL-cholesterol < 1 mmol/l. In subjects treated with atorvastatin to lower their LDL-cholesterol levels, torcetrapib further lowered LDL-cholesterol while increasing HDL-cholesterol. In conclusion, raising HDL-cholesterol with inhibitors of CETP is a new approach to coronary artery disease that requires further investigation, especially in patients with coronary artery disease. |
| | |
Authors:
|
Sheila A Doggrell |
Related Documents
:
|
9055055 - A study to determine the response of coronary atherosclerosis to raising low high densi... 17536125 - Pistachio nut consumption and serum lipid levels. 1733055 - Serum lipid abnormalities in pediatric liver transplant patients. 9315415 - A study on the effects of norplant implantable contraceptive on lipid, lipoprotein, and... 7092745 - Oosporein-toxicosis in the turkey poult. 7981885 - A citrus fruit-exclusion diet in sensitive patients and its influence on specific antib... |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: Expert opinion on investigational drugs Volume: 13 ISSN: 1744-7658 ISO Abbreviation: Expert Opin Investig Drugs Publication Date: 2004 Oct |
Date Detail:
|
Created Date: 2004-10-05 Completed Date: 2006-04-06 Revised Date: 2007-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 9434197 Medline TA: Expert Opin Investig Drugs Country: England |
Other Details:
|
Languages: eng Pagination: 1365-8 Citation Subset: IM |
Affiliation:
|
Doggrell Biomedical Communications, 47 Caronia Crescent, Lynfield, Auckland, New Zealand. s.doggrell@xtra.com |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Carrier Proteins
/
antagonists & inhibitors* Cholesterol Ester Transfer Proteins Cholesterol, HDL / metabolism* Cholesterol, LDL / metabolism Clinical Trials as Topic Clofibric Acid / pharmacology, therapeutic use Coronary Artery Disease / drug therapy* Glycoproteins / antagonists & inhibitors* Humans Quinolines / pharmacology, therapeutic use* |
| Chemical | |
Reg. No./Substance:
|
0/CETP protein, human; 0/Carrier Proteins; 0/Cholesterol Ester Transfer Proteins; 0/Cholesterol, HDL; 0/Cholesterol, LDL; 0/Glycoproteins; 0/Quinolines; 262352-17-0/torcetrapib; 882-09-7/Clofibric Acid |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Suramin: potential in acute liver failure.
Next Document: SMi 4th Annual Conference on Neurodegenerative Disorders: a focus on Alzheimer's and Parkinson's dis...